Alterity Therapeutics Limited (ATH), formerly known as Prana Biotechnology Limited, is a clinical-stage biotechnology company dedicated to neurodegenerative diseases. The company focuses on commercialising research related to Parkinsonian movement disorders, Alzheimer's disease, Huntington's disease, and other neurodegenerative conditions. Alterity aims to advance treatments and therapies for these challenging and complex diseases through its innovative research and development efforts.